Skip to main content

Table 4 Summary of variation in approach to implementing anaemia screening and MSSA decolonisation pathways, rates of implementation and primary outcome reporting

From: Scaling up Quality Improvement for Surgical Teams (QIST)—avoiding surgical site infection and anaemia at the time of surgery: a cluster randomised controlled trial of the effectiveness of quality improvement collaboratives to introduce change in the NHS

Trial arm

Approach to diagnosing anaemia or MSSA decolonisation

Total number of procedures performed during trial 12-month measurement period (n range)

Procedures where records were provided (included in QIST analysis) (% range of total procedures performed)

Procedures for which pre-op pathway was implemented as part of QISTa (% range of total procedures performed)

Reported potential SSIs, n

All SSIs confirmed by IOCb (% range of reported potential SSIs)

IOC confirmed deep SSIs by causative organism (% range of procedures included in QIST)

Procedures requiring blood transfusion (% range)

Anaemia

Variation in Hb thresholds for diagnosing anaemia was observed. Lower limits ranged from 105 to 115g/L and upper limits ranged from 115 to 129g/L.

Not all Trusts used sex-dependant thresholds

397–2805

20.4–100%

16.4–98.1

0–25

11–100%

MSSA: 0–0.7%

Anyc: 0–1.1%

0–11.6%

Infection

6 Trusts screened and only decolonised MSSA-positive patients. MSSA-positive rate ranged from 21.9 to 31.2%

10 Trusts decolonised all patients without screening

457–2786

22.6–100%

0–94.1%

0–75

9–100%

MSSA: 0–0.7%

Anyc: 0–2.1%

0–7.7%

  1. Further details are provided in Supplementary Files 2 and 3
  2. aDuring 12-month trial measurement period busing either CDC or PHE definitions for deep or superficial SSI cincluding MSSA